News
Hosted on MSN27d
AXSM Stock Down Despite ADHD Study Meeting Primary EndpointImage Source: Zacks Investment Research The double-blind, placebo-controlled phase III FOCUS study evaluated solriamfetol versus placebo in adults with ADHD ... The stock price decline could ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback